- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Plymouth Meeting Today
By the People, for the People
Inovio Pharmaceuticals Reports Q4 2025 Earnings
Biotech firm focused on DNA-based immunotherapies and vaccines announces latest financial results.
Mar. 13, 2026 at 3:53am
Got story updates? Submit your updates here. ›
Inovio Pharmaceuticals, a biotechnology company specializing in DNA-based immunotherapies and vaccines, has reported its financial results for the fourth quarter of 2025. The company, headquartered in Plymouth Meeting, Pennsylvania, is led by CEO J. Joseph Kim and is focused on developing treatments and preventative measures for infectious diseases and cancers.
Why it matters
As a leader in the emerging field of DNA-based immunotherapies, Inovio's quarterly earnings provide insight into the progress and challenges facing the company's pipeline of investigational treatments, including its COVID-19 vaccine candidate INO-4800. The report also sheds light on Inovio's financial standing and ability to fund ongoing research and development efforts.
The details
Inovio's Q4 2025 report covers the company's financial performance over the last three months of the year, including revenue, expenses, and net income or loss. The report likely includes updates on the status of Inovio's clinical trials, regulatory milestones, and partnerships with other organizations. As a publicly traded company, Inovio is required to regularly disclose its financial results to shareholders and the broader investment community.
- Inovio Pharmaceuticals announced their Q4 2025 earnings on March 12, 2026.
The players
Inovio Pharmaceuticals
A biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers.
J. Joseph Kim
The Chief Executive Officer of Inovio Pharmaceuticals, guiding the company's evolution from early-stage research to mid-stage clinical development since 2016.
The takeaway
Inovio's Q4 2025 earnings report provides a window into the company's progress in advancing its pipeline of DNA-based immunotherapies and vaccines, including its high-profile COVID-19 vaccine candidate. The report will be closely watched by investors and industry observers as Inovio seeks to demonstrate its ability to translate its innovative technology into commercially viable products.
